# Galápagos

### Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference

## Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.

Onno van de Stolpe, CEO, will present on Thursday, January 13 at 14.15 CET (8.15 a.m. ET). The presentation will be a live audio webcast and can be accessed via the following <u>link</u>. A replay of the webcast will be available on the Galapagos' website at <u>www.glpg.com</u>.

#### About Galapagos

Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at <u>www.glpg.com</u>.

#### Contacts

**Investors:** Sofie Van Gijsel Head of Investor Relations +1 781 296 1143

Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com

Media: Marieke Vermeersch Head of Corporate Communications +32 479 49 06 03 communications@glpg.com

#### Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.